14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
×
Home
/
Stock Analysis
/
Compare Terminal
/
ICCC vs INTG
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
ICCC vs INTG: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
ICCC Wins Head-to-Head Institutional Verdict (4–1 across 6 Pillars · 5–3 Matrix Metrics)
ICCC Overall Winner
6-Pillar Tally: ICCC 4 – 1 INTG (1 Tie)
Matrix Metrics: ICCC 5 – 3 INTG
As of Nov 16, 2026, Immucell Corp (ICCC) is the stronger overall head-to-head candidate over Intergroup Corporation (The) (INTG) in the Tradestie Institutional Equity Comparison Engine, winning 5–3 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). ICCC carries a Unified Composite Score of 43.8/100 (HOLD) at $11.42 (N/M Forward P/E, 15.2% operating margin), whereas INTG carries 32.5/100 (SELL) at $41.48 (N/M Forward P/E, 16.1% operating margin).
ICCC
NASDAQ
Head-to-Head Winner
Immucell Corp
In Vitro & In Vivo Diagnostic Substances
Market Cap
$97.7M
TTM Revenue
$67M
Forward P/E
N/M
Beta / 30D Vol
0.24β · 46% Vol
Unified Composite Score
43.8 / 100
HOLD
Tech 15.0
Fund 48.0
Flow 50.0
Mom 50.0
Weinstein Technical Phase
Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (0.9% over 20 days), RSI 68
RSI-14: 67.5 · SMA20: $10.37 · SMA50: $10.13
INTG
NASDAQ
Intergroup Corporation (The)
Operators Of Apartment Buildings
Market Cap
$89.7M
TTM Revenue
$74M
Forward P/E
N/M
Beta / 30D Vol
-0.14β · 42% Vol
Unified Composite Score
32.5 / 100
SELL
Tech 15.0
Fund 33.0
Flow 50.0
Mom 30.0
Weinstein Technical Phase
Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (3.7% over 20 days), RSI 70
RSI-14: 70.4 · SMA20: $37.57 · SMA50: $35.37
6-Pillar Scorecard Institutional Category Breakdown (ICCC 4 – 1 INTG)
Columns: Metric · ICCC · INTG
1. Valuation Multiples
ICCC
Forward P/E
N/M
N/M
Trailing P/E
56.6x
58.8x
PEG Ratio
N/M
N/M
EV / Revenue
1.6x
3.7x
2. Growth & Scale
INTG
Revenue Growth (YoY)
+11.5%
+13.3%
Earnings Growth (YoY)
+259.9%
N/A
TTM Revenue (USD)
$67M
$74M
Market Cap
$97.7M
$89.7M
3. Profitability & Quality
ICCC
Gross Margin
40.3%
29.1%
Operating Margin
15.2%
16.1%
Net Profit Margin
2.6%
2.2%
Return on Equity (ROE)
2.6%
0.0%
4. Balance Sheet & Cash Flow
ICCC
Cash Generation (TTM)
$7.4M
$2.8M
Cash Flow Margin
11.0%
3.8%
Net Cash / Leverage
$13M Net Debt (0.44x D/E)
$186M Net Debt
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
Tie
Options Structure Phase
UNCLASSIFIED
UNCLASSIFIED
Current IV / %ile
N/A (N/A)
N/A (N/A)
Put/Call OI Skew
N/A
N/A
OBV Trend / Tech Phase
NEUTRAL · Markup
NEUTRAL · Markup
6. R&D & Supply-Chain Moat
ICCC
OpEx & R&D Intensity
25.1% of Rev ($17M)
13.0% of Rev ($9.6M)
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Scale & Operating Efficiency Moat
Scale & Operating Efficiency Moat
Supply-Chain Role
Biotechnology Operator
Lodging Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: ICCC (5) vs INTG (3)
Institutional Metric
ICCC
INTG
Criterion
Row Edge
Market Capitalization
Scale
$97.7M
$89.7M
Larger Scale
Tie
Trailing P/E Ratio
Valuation
56.6x
58.8x
Lower Multiple
ICCC
Forward P/E Ratio
Valuation
N/M
N/M
Lower Multiple
Tie
Revenue Growth (YoY)
Growth
+11.5%
+13.3%
Higher Growth
INTG
Operating Margin (TTM)
Profitability
15.2%
16.1%
Higher Margin
INTG
Net Profit Margin
Profitability
2.6%
2.2%
Higher Margin
ICCC
Return on Equity (ROE)
Capital Efficiency
2.6%
0.0%
Higher ROE
ICCC
52-Week Range Position
Momentum
91% ($5–$12)
61% ($25–$52)
Stronger Trend
ICCC
Beta / 30D Volatility
Risk Regime
0.24β · 46% Vol
-0.14β · 42% Vol
Lower Realized Risk
INTG
Unified Institutional Score
Composite Signal
43.8 / 100 (HOLD)
32.5 / 100 (SELL)
Higher Composite
ICCC
Trailing 12M Revenue (USD)
Operating Scale
$67M
$74M
FX-Normalized USD
Scale
Gross Profit Margin (TTM)
Unit Pricing Power
40.3%
29.1%
Higher Margin
Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 1.6x EV/Rev
N/M PEG · 3.7x EV/Rev
Lower Multiple
Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$7.4M ($13M Net Debt (0.44x D/E))
$2.8M ($186M Net Debt)
Higher Cash / Net Cash
Solvency
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M
3M
6M
1Y
1M Horizon
INTG +21.87 pp
ICCC:
+6.23%
·
INTG:
+28.1%
3M Horizon
INTG +1.2 pp
ICCC:
+17.01%
·
INTG:
+18.21%
6M Horizon
ICCC +4.63 pp
ICCC:
+15.24%
·
INTG:
+10.61%
1Y Horizon
ICCC +66.8 pp
ICCC:
+88.76%
·
INTG:
+21.96%
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
Split-Invariant USD Revenue & Operating Margin (%)
Period
ICCC Revenue
INTG Revenue
ICCC Op. Margin
INTG Op. Margin
Margin Leader
FY2019
$10M
$70M
-7.0%
20.3%
INTG
FY2020
$20M
$60M
-9.0%
8.4%
INTG
FY2021
$20M
$30M
1.3%
-17.0%
ICCC
FY2022
$20M
$50M
-12.4%
7.8%
INTG
FY2023
$20M
$60M
-32.9%
7.5%
INTG
FY2024
$30M
$60M
-6.2%
2.5%
INTG
FY2025
$30M
$60M
6.0%
11.9%
INTG
FY2026
N/A
$70M
N/A
16.0%
INTG
ICCC
UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV
N/A
IV Percentile
N/A
Put/Call OI Skew
N/A
IV Regime
Unclassified
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
NEUTRAL
OBV Flow
NEUTRAL
INTG
UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV
N/A
IV Percentile
N/A
Put/Call OI Skew
N/A
IV Regime
Unclassified
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
NEUTRAL
OBV Flow
NEUTRAL
ICCC Moat Profile
Scale & Operating Efficiency Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $97.7M market capitalization and 15.2% operating margin.
OpEx & R&D Reinvestment
25.1% of Rev ($17M)
90D Engineering Disclosures
0 Published
INTG Moat Profile
Scale & Operating Efficiency Moat
Lodging Operator
Competes within the Lodging value chain with $89.7M market capitalization and 16.1% operating margin.
OpEx & R&D Reinvestment
13.0% of Rev ($9.6M)
90D Engineering Disclosures
0 Published
Investor FAQ ICCC vs INTG Key Questions & Quantitative Answers
Is ICCC or INTG a better stock to buy right now?
As of Nov 16, 2026, Immucell Corp (ICCC) is the stronger overall head-to-head candidate over Intergroup Corporation (The) (INTG) in the Tradestie Institutional Equity Comparison Engine, winning 5–3 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). ICCC carries a Unified Composite Score of 43.8/100 (HOLD) at $11.42 (N/M Forward P/E, 15.2% operating margin), whereas INTG carries 32.5/100 (SELL) at $41.48 (N/M Forward P/E, 16.1% operating margin). Technically, ICCC sits in a Markup phase (RSI 67.5, UNCLASSIFIED options structure) and INTG sits in a Markup phase (RSI 70.4, UNCLASSIFIED options structure).
Does ICCC or INTG have stronger revenue and earnings growth?
INTG leads the Growth & Scale pillar: ICCC posts +11.5% YoY revenue growth and +259.9% YoY earnings growth on $67M TTM revenue (40.3% gross margin, 15.2% operating margin), compared with INTG at +13.3% YoY revenue growth and N/A YoY earnings growth on $74M TTM revenue (29.1% gross margin, 16.1% operating margin). Across the 8-period historical trajectory (FY2019 to FY2026), ICCC cumulative revenue shifted +200.0% while INTG shifted +0.0%. In operating R&D and SG&A reinvestment, ICCC deploys 25.1% of Rev ($17M) (0 90-day corporate R&D disclosures) versus 13.0% of Rev ($9.6M) (0 disclosures) for INTG.
Is ICCC or INTG cheaper on valuation?
ICCC screens cheaper on headline valuation multiples. ICCC trades at N/M Forward P/E, 56.6x Trailing P/E, N/M PEG, and 1.6x EV/Revenue (11.0% FCF margin), whereas INTG trades at N/M Forward P/E, 58.8x Trailing P/E, N/M PEG, and 3.7x EV/Revenue (3.8% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ICCC (2.6% ROE) versus INTG (0.0% ROE) capital efficiency.
How is options market volatility positioned on ICCC vs INTG?
In options market volatility and institutional positioning, ICCC carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.24β · 46% Vol realized risk). By comparison, INTG carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-0.14β · 42% Vol realized risk).
Immucell Corp (ICCC) Research Suite
Intergroup Corporation (The) (INTG) Research Suite
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.